289 related articles for article (PubMed ID: 33159426)
21. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
22. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.
Zahoor H; Barata PC; Jia X; Martin A; Allman KD; Wood LS; Gilligan TD; Grivas P; Ornstein MC; Garcia JA; Rini BI
J Immunother Cancer; 2018 Oct; 6(1):107. PubMed ID: 30333065
[TBL] [Abstract][Full Text] [Related]
23. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma.
Yamamoto Y; Matsuyama H; Matsumoto H; Sakano S; Fuji N; Oba K; Yamamoto M; Kamiryo Y; Hiragino T; Nagao K; Takai K; Aoki A
Jpn J Clin Oncol; 2020 Feb; 50(2):214-220. PubMed ID: 31755525
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up.
Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Hashimoto Y; Takagi T; Ishida H; Kondo T; Tanabe K
Jpn J Clin Oncol; 2022 Jul; 52(7):785-790. PubMed ID: 35373823
[TBL] [Abstract][Full Text] [Related]
26. Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study.
Ishihara H; Kondo T; Takagi T; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Tanabe K
Target Oncol; 2018 Oct; 13(5):611-619. PubMed ID: 30232691
[TBL] [Abstract][Full Text] [Related]
27. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
[TBL] [Abstract][Full Text] [Related]
28. Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma.
José JM; Jose M; Silverio R; Federico V; Isabel C; Martin OA; Inmaculada B; Cristina C; Julia HC; Dolores TM; Jose G; Paola P; Nieves DP; Vicent A; Sara B; Sara M; Julián L; Manuel S; Del Carmen MM; Ángel CM; Vicente G
Clin Transl Oncol; 2020 Sep; 22(9):1517-1523. PubMed ID: 32048159
[TBL] [Abstract][Full Text] [Related]
29. Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study.
Mollica V; Rizzo A; Tassinari E; Giunchi F; Schiavina R; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
Anticancer Drugs; 2021 Jan; 32(1):74-81. PubMed ID: 33290315
[TBL] [Abstract][Full Text] [Related]
30. Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
Tachibana H; Kondo T; Ishihara H; Fukuda H; Yoshida K; Takagi T; Izuka J; Kobayashi H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(4):646-653. PubMed ID: 33212488
[TBL] [Abstract][Full Text] [Related]
31. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647
[TBL] [Abstract][Full Text] [Related]
32. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
Koshkin VS; Barata PC; Zhang T; George DJ; Atkins MB; Kelly WJ; Vogelzang NJ; Pal SK; Hsu J; Appleman LJ; Ornstein MC; Gilligan T; Grivas P; Garcia JA; Rini BI
J Immunother Cancer; 2018 Jan; 6(1):9. PubMed ID: 29378660
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
Santoni M; Aurilio G; Massari F; Grande E; Matrana MR; Rizzo M; De Giorgi U; Incorvaia L; Martignetti A; Molina-Cerrillo J; Zabalza IO; Mollica V; Rizzo A; Battelli N; Porta C
Clin Genitourin Cancer; 2022 Jun; 20(3):285-295. PubMed ID: 35305916
[TBL] [Abstract][Full Text] [Related]
34. A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma.
Bando Y; Hinata N; Omori T; Fujisawa M
BMJ Open; 2019 Dec; 9(12):e030522. PubMed ID: 31826889
[TBL] [Abstract][Full Text] [Related]
35. Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(5):793-801. PubMed ID: 33324983
[TBL] [Abstract][Full Text] [Related]
36. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
[TBL] [Abstract][Full Text] [Related]
37. Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era.
Ishihara H; Nemoto Y; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Target Oncol; 2022 May; 17(3):307-319. PubMed ID: 35460475
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review.
Gamulin M; Nham E; Rkman D; Antunac Golubić Z; Likić R
Croat Med J; 2020 Aug; 61(4):326-332. PubMed ID: 32881430
[TBL] [Abstract][Full Text] [Related]
39. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S
Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497
[TBL] [Abstract][Full Text] [Related]
40. Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study.
Grimm MO; Grünwald V; Müller-Huesmann H; Ivanyi P; Schostak M; von der Heyde E; Schultze-Seemann W; Belz H; Bögemann M; Wang M; Herber M; Bedke J;
Eur Urol Focus; 2022 Sep; 8(5):1289-1299. PubMed ID: 34953677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
